We next investigated the utility of CD55 in predicting outcomes of patients with endometrioid ovarian cancer by using the Kaplan-Meier plotter biomarker assessment database (Gyorffy et al., 2012). This evidence concerns the gene CD55 and ovarian endometrioid adenocarcinoma.